ActoGeniX, NV: Series A $26M

ActoGeniX, (Belgium) is developing a pipeline of therapeutic products based on its TopAct™ technology platform with it’s most advanced candidate for Crohn’s disease, closed a $26M Series A led by GIMV and Life Sciences Partners. New investors include Aescap, Ventech and Baekeland Fonds.

BioBehavioral Diagnostics: Series A $8.5M

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

AlphaVax, Inc.: Series E $12.65M

AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.

NextWave Pharma, Inc.: Series B $40M

NextWave Pharma (Buffalo Grove, Ill) a pediatric drug company operating in stealth mode, closed $40M in Series B funding. The round was led by return investors Sofinnova Ventures and Vivo Ventures.

Locus Pharma, Inc.: Series D $30.2M

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.

InnerPulse, Inc.: Series C $50M

InnerPulse (Research Triangle Park, NC) a developer of implantable defibrillators raised $50M in a Series C financing. Investors included Johnson & Johnson Development Corp., Medtronic, Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Healthcare Ventures.

Omeros, Inc.: Series E $63M

Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.

Prosensa Holding BV: Series A $18M

Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.

Ception Therapeutics Inc.: Series C $63M

Ception Therapeutics (Malvern, PA) a drug company developing anti-inflammatories, raised a $63M Series C round. The financing was led by Essex Woodlands Health Ventures, and was joined by Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.

Targanta, Inc.: Series C $70M

Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.